Slingshot Insights | Mrk Overview

MRK Overview

Upcoming Projects (MRK)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (MRK)

Quarterly Survey: LR-MDS Pts RBC Transfusions and Reblozyl (luspatercept) January 2024
Tickers: BMY, GERN, ELRN, MRK, XLRN
Executed On: Jan 24, 2024 at 10:49 AM EST
Digging into the phase 2 KRYSTAL-7 clinical trial results of adagrasib with pembrolizumab as a treatment for non-small cell lung cancer as presented at ESMO 2023
Tickers: MRTX, MRK
Executed On: Nov 29, 2023 at 01:30 PM EST
Key Takeaways from ESMO 2023: A conversation with an oncologist attending the conference
Tickers: SGEN, MRK, NVS, MRTX, JNJ
Executed On: Nov 07, 2023 at 01:00 PM EST
Quarterly Survey: LR-MDS Pts RBC Transfusions and Reblozyl (luspatercept) - October 2023
Tickers: BMY, MRK, GERN, ELRN
Executed On: Nov 02, 2023 at 05:25 PM EDT
A broad discussion looking at the competitive landscape of the Life Science antibody and reagent market
Tickers: TMO, MRK, A, BIO
Executed On: Sep 20, 2023 at 10:00 AM EDT
A Second Look: Discussing the potential of the Optilume Benign Prostatic Hyperplasia Catheter and Balloon system from Urotronic and how it compares to medications from Merck, GSK, and Astellas.
Tickers: UROTRONIC, ALPMY, MRK, GSK
Executed On: Sep 01, 2023 at 08:00 AM EDT
Discussing the potential of the Optilume Benign Prostatic Hyperplasia Catheter and Balloon system from Urotronic and how it compares to medications from Merck, GSK, and Astellas.
Tickers: UROTRONIC, ALPMY, MRK, GSK
Executed On: Aug 25, 2023 at 09:00 AM EDT
Diving into the label expansion for Merck's Prevymis (letermovir) for prophylaxis of cytomegalovirus (CMV) disease in adult kidney transplant recipients
Ticker: MRK
Executed On: Aug 01, 2023 at 04:00 PM EDT
Quarterly Survey: LR-MDS Pts RBC Transfusions and Reblozyl (luspatercept) - July 2023
Tickers: BMY, MRK, GERN, ELRN
Executed On: Aug 01, 2023 at 03:55 PM EDT
Quarterly Survey: BMY's Reblozyl (luspatercept) and LR-MDS requiring Red Blood Cell Transfusions May 2023
Tickers: BMY, XLRN, MRK, GERN
Executed On: May 10, 2023 at 12:29 PM EDT
Discussing therapeutics in development for melanoma including Moderna/Merck's mRNA-4157 cancer vaccine and Iovance Biotherapeutics' TIL therapy, lifileucel.
Tickers: MRNA, IOVA, MRK
Executed On: May 09, 2023 at 10:30 AM EDT
Understanding the roles TIGIT targeting drugs play in cancer immunotherapy and efficacy compared to PD-1 inhibitors
Tickers: RHHBY, MRK, GSK, BMS, RCUS
Executed On: May 05, 2023 at 04:30 PM EDT
A Second View: Delving into the Phase 3 STELLAR trial data released at ACC 2023 on Merck's sotatercept for treating PAH
Tickers: MRK, UTHR
Executed On: Apr 11, 2023 at 06:00 PM EDT
Delving into the Phase 3 STELLAR trial data released at ACC 2023 on Merck's sotatercept for treating PAH
Tickers: MRK, UTHR
Executed On: Apr 03, 2023 at 05:30 PM EDT
Digging in to the Phase 2b data presented at the AAC Conference for Merck's oral PCSK9 inhibitor, MK-0616, in patients with hypercholesterolemia
Ticker: MRK
Executed On: Mar 16, 2023 at 09:00 AM EDT
Examining the clinical landscape of renal disease and the potential of anticoagulant therapies in this space for the prevention of cardiovascular events, including Merck's MK-2060.
Ticker: MRK
Executed On: Sep 09, 2022 at 01:00 PM EDT
A look at Quviviq for treatment in adults with insomnia and how it compares to competitors in this space
Tickers: IDRSF, MRK
Executed On: Aug 31, 2022 at 01:30 PM EDT
Discussing Bellus BLU-5937 against Merck's gefapixant in Chronic cough, following recent Phase 2b results and FDA meeting
Tickers: BLU, MRK
Executed On: Jul 14, 2022 at 10:00 AM EDT
A look at Verquvo following its FDA approval to reduce the risk of cardiovascular death and heart failure hospitalization
Ticker: MRK
Executed On: May 04, 2022 at 02:30 PM EDT
A Second View: Discussing Welireg (Belzutifan) as a treatment in patients with von Hippel-Lindau (VHL) disease with associated renal cell carcinoma
Ticker: MRK
Executed On: Mar 23, 2022 at 04:30 PM EDT
Discussing Welireg (Belzutifan) as a treatment in patients with von Hippel-Lindau (VHL) disease with associated renal cell carcinoma
Ticker: MRK
Executed On: Mar 15, 2022 at 10:00 AM EDT
A Second View: Discussing the Pneumococcal vaccine market and where a new vaccine could potentially fit in
Tickers: PFE, PCVX, GSK, MRK, Affinivax, ALPMY
Executed On: Jan 07, 2022 at 10:00 AM EST

Expired Projects (MRK)

Digging into Merck's Keytruda as a first-line monotherapy in locally advanced or metastatic NSCLC with TPS of ≥1
Ticker: MRK
Execute By: May 09, 2019
Discussing the Landscape of the Injectable Long-Acting Insulin Market for Merck's Glargine (MK-1293) in Type 1 & 2 Diabetes Following Expected April PDUFA
Tickers: MRK, SNY, LLY, NVO
Execute By: Apr 14, 2017
Assessing the Potential of AstraZeneca's (AZN) Durvalumab + TapImmune's (TPIV) TPIV 200 in Platinum-Resistant Ovarian Cancer Ahead of Phase II Initiation This Quarter
Tickers: AZN, MRK, BMY, TPIV, RHHBY
Execute By: May 17, 2016
Evaluating the Market Potential of Hua Medicine's HMS5552 in Type II Diabetes Ahead of Mid-Year Phase II Readout. Does the drug have potential to derail the success of major players in the space?
Tickers: HUA MEDICINE, ABT, AZN, NVS, NVO, MRK, SNY, GSK, Lupin Pharmaceuticals, RHHBY
Execute By: May 11, 2016
A discussion on the potential of Lannett's (LCI) generic chemo agent temozolomide capsules to gain a portion of Merck's (MRK) market share for temodar in a certain type of brain tumor
Tickers: MRK, LCI
Execute By: Mar 14, 2016
To see if we can get the specific DOJ requests to Pharma companies on drug pricing. These investigations have been confirmed in 10q filings.
Tickers: MRK, VRX, LLY
Execute By: Mar 04, 2016

Upcoming & Overdue Catalysts (MRK)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (MRK)

FDA Approves Merck’s (MRK) KEYTRUDA (pembrolizumab) for the Adjuvant Treatment of Patients with Melanoma with Involvement of Lymph Node(s) Following Complete Resection
Ticker: MRK
Occurred on: Feb 19, 2019
European Commission Approves Merck’s KEYTRUDA (pembrolizumab) in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of Patients with Metastatic Nonsquamous NSCLC, with No EGFR or ALK Genomic Tumor Aberration
Ticker: MRK
Occurred on: Sep 10, 2018
Merck’s (MRK) KEYTRUDA (pembrolizumab) Phase 2 KEYNOTE-158 Study in Patients with Advanced Small Cell Lung Cancer (SCLC) Data Released
Ticker: MRK
Occurred on: Jun 04, 2018
Bristol-Myers Squibb's (BMY) Phase 3 CheckMate of Opdivo Plus Low-Dose Yervoy in Lung Cancer Patients with High Tumor Mutational Burden Data Presented at AACR
Tickers: BMY, MRK
Occurred on: Apr 16, 2018
First-Line Lung Cancer Data and Other New Research from Merck’s Broad Oncology Program to be Presented at AACR Annual Meeting
Ticker: MRK
Occurred on: Apr 16, 2018
Top-line data from the Open label Phase 2 trial comparing ridinilazole to fidaxomicin is expected to be reported in Q2 2017
Tickers: SMMT, MRK
Occurred on: Oct 09, 2017
PDUFA for Keytruda(pembrolizumab) in treating patients with recurrent or advanced gastric or gastroesophageal junction adenocarcinoma who have already received two or more lines of chemotherapy date set for Sept. 22, 2017
Ticker: MRK
Occurred on: Sep 22, 2017
The results of the REVEAL study of Anacetrapib (MK-0859) in LDL-C lowering will be presented at the European Society of Cardiology meeting on Aug. 29, 2017
Ticker: MRK
Occurred on: Aug 29, 2017
FDA Decision Expected By April 5th for Merck's (MRK) Glargine (MK-1293) in Type 1 and Type 2 Diabetes
Tickers: MRK, SNY, LLY, NVO
Occurred on: Jul 20, 2017
MRK's CETP CV outcomes for hypercholesterolemia expected in Q1 2017
Tickers: MRK, AMGN, ESPR
Occurred on: Jun 27, 2017
Aralez Pharmaceuticals (ARLZ) commences full-scale commercial launch of former Merck (MRK) product Zontivity
Tickers: ARLZ, MRK
Occurred on: Jun 07, 2017
PUDFA date for KEYTRUDA in treating Microsatellite Instability-High Cancer set for June 9, 2017
Ticker: MRK
Occurred on: May 25, 2017
FDAA approves Merck & co. (MRK) product KEYTRUDA® (pembrolizumab) for the treatment of non-squamous non-small cell lung cance (NSCLC)
Ticker: MRK
Occurred on: May 10, 2017
PDUFA Date of August 27 for Merck KGaA's (MKGAY) Biologics License Application for Avelumab in Treatment of Metastatic Urothelial Carcinoma With Disease Progression on or After Platinum-Based Chemotherapy
Tickers: MKGAY, MRK, EMD Serono
Occurred on: May 09, 2017
Merck Completes Enrollment in Pivotal Phase 3 “EPOCH” Trial Investigating the Efficacy and Safety of Verubecestat in Patients with Mild-to-Moderate Alzheimer’s Disease; primary trial completion expected in July 2017.
Ticker: MRK
Occurred on: Apr 27, 2017
PUDFA date for KEYTRUDA in treating Relapsed or Refractory Classical Hodgkin Lymphoma set on March 15 2017
Ticker: MRK
Occurred on: Mar 14, 2017
Merck (MRK) and Pfizer (PFE) Plan to Submit NDA By End of 2016 for Ertugliflozin in Combination with Januvia (sitagliptin) and Metformin in Treatment of Type 2 Diabetes
Tickers: MRK, PFE
Occurred on: Mar 06, 2017
OncoSec's (ONCS) ImmunoPulse Il-12 Granted Fast Track Status by FDA for Metastatic Melanoma Following Progression on Merck's (MRK) KEYTRUDA or Bristol-Myers Squibb's (BMY) Opdivo
Tickers: ONCS, BMY, MRK
Occurred on: Feb 27, 2017
Merck (MRK) Presents Phase 3 Results Evaluating Inactivated Varicella Zoster Vaccine (VZV) V212 for the Prevention of Herpes Zoster (HZ) (Shingles)
Ticker: MRK
Occurred on: Feb 24, 2017
OncoSec Medical (ONCS) Phase 2 Results Evaluating ImmunoPulse IL-12 and Merck's (MRK) Keytruda in Metastatic Melanoma
Tickers: ONCS, MRK
Occurred on: Feb 23, 2017
MacroGenics (MGNX) to complete Phase 1b/2 combination study of Margetuximab and Pembrolizumab in patients with advanced, metastatic gastric cancer in late 2016
Tickers: MGNX, MRK
Occurred on: Dec 13, 2016
Interim Phase 1b/2 Results for Merck's (MRK) Keytruda and Eisai's (ESALY) Halaven in Triple-Negative Breast Cancer (TNBC) Presented at the San Antonio Breast Cancer Symposium
Ticker: MRK
Occurred on: Dec 12, 2016
FDA Grants Priority Review to Merck’s (MRK) Supplemental Biologics License Application (sBLA) Seeking Approval for KEYTRUDA (pembrolizumab) for New Indication in Microsatellite Instability-High Cancer
Ticker: MRK
Occurred on: Nov 28, 2016
Merck (MRK) Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
Ticker: MRK
Occurred on: Nov 13, 2016
Merck (MRK) to Present New Data on ZEPATIER (elbasvir and grazoprevir) and Chronic Hepatitis C Clinical Development Programs at The Liver Meeting 2016
Ticker: MRK
Occurred on: Nov 12, 2016
OncoSec Medical's (ONCS) Interim Results from Phase 2 Study of ImmunoPulse IL-12 and Merck's (MRK) KEYTRUDA in Unresectable Metastatic Melanoma to be Presented at the Society for Immunotherapy of Cancer Annual Meeting
Tickers: ONCS, MRK
Occurred on: Nov 11, 2016
Merck's (MRK) Marketing Authorization Application (MAA) for Avelumab in Rare Skin Cancer Validated by European Medicines Agency (EMA)
Ticker: MRK
Occurred on: Oct 31, 2016
Merck's (MRK) Keytruda Approved By FDA for New Indication in Metastatic Non-Small Cell Lung Cancer (NSCLC) With High PD-L1 Expression and No EGFR or ALK Mutations
Ticker: MRK
Occurred on: Oct 24, 2016
Merck (MRK) Announces Phase 3 KEYNOTE-045 Results Evaluating Keytruda in Advanced Urothelial Cancer
Ticker: MRK
Occurred on: Oct 21, 2016
FDA has requested the submission of new data and analyses from the MODIFY I and MODIFY II clinical trials. PDUFA date extended to Oct 23 2016
Ticker: MRK
Occurred on: Oct 21, 2016
Merck (MRK) Announces Phase 3 Data Evaluating Letermovir in Clinically Significant Cytomegalovirus (CMV) Infection in CMV-Seropositive Adults Who Have Undergone an Allogeneic Hematopoietic Stem Cell Transplant (HSCT)
Ticker: MRK
Occurred on: Oct 19, 2016
Incyte (INCY) and Merck (MRK) Present Updated Results on Phase 1 ECHO-202 Trial Evaluating Epacadostat + Keytruda in Treatment-Naive Advanced/Metastatic Melanoma Patients
Tickers: INCY, MRK
Occurred on: Oct 07, 2016
FDA Announces Black Box Requirement for Risk of HBV Reactivation for at Least 9 Brand Name Drugs in Hepatitis C Treatment
Tickers: GILD, ABBV, MRK
Occurred on: Oct 05, 2016
First Patient Enrolled in Bayer (BAYRY) and Merck's (MRK) Phase 3 VICTORIA Trial Assessing Vericiguat in Chronic Heart Failure Without Reduced Ejection Fraction
Tickers: BAYRY, MRK
Occurred on: Sep 28, 2016
BioLineRX (BLRX) Initiates Phase 2a Trial Evaluating BL-8040 + Merck's (MRK) KEYTRUDA in Treatment of Pancreatic Cancer
Tickers: BLRX, MRK
Occurred on: Sep 20, 2016
Sanofi (SNY) Files Lawsuit Against Merck (MRK) Over Violation of As Many as 10 Patents, Including Diabetes Treatment Lantus and Insulin Delivery Device soloSTAR
Tickers: SNY, MRK
Occurred on: Sep 19, 2016
Merck (MRK) and Pfizer (PFE) Announce Phase 3 Results for Type 2 Diabetes Candidate Ertugliflozin
Tickers: MRK, PFE
Occurred on: Sep 15, 2016
Teva (TEVA) Launches Generic Version of Merck's CUBICIN for Complicated Skin and Bloodstream Infections in U.S
Tickers: MRK, TEVA
Occurred on: Sep 15, 2016
FDA Accepts Supplemental Biologics License Application, Assigns Priority Review and Grants Breakthrough Therapy Designation to Merck’s KEYTRUDA (pembrolizumab) for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer
Ticker: MRK
Occurred on: Sep 07, 2016
Merck's osteoporosis candidate odanacatib development terminated
Ticker: MRK
Occurred on: Sep 02, 2016
NDA to be Filed for Odanacatib for Treatment of Osteoporosis in 2016 Pending Long Safety Review
Ticker: MRK
Occurred on: Sep 02, 2016
Phase 1b study assessing AFM13/KEYTRUDA combo in lymphoma to be initiated in the first half of 2016
Tickers: AFMD, MRK
Occurred on: Aug 10, 2016
FDA Approves Merck’s KEYTRUDA (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy
Ticker: MRK
Occurred on: Aug 09, 2016
Results from Merck’s Phase 3 Study Evaluating ZEPATIER (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published in Annals of Internal Medicine
Ticker: MRK
Occurred on: Aug 09, 2016
Merck Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for MK-1293, an Investigational Follow-On Biologic Insulin Glargine; Marketing Authorization Application to the European Medicines Agency Currently Under Review
Ticker: MRK
Occurred on: Aug 05, 2016
Merck’s KEYTRUDA (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1
Ticker: MRK
Occurred on: Aug 02, 2016
Merck Receives Breakthrough Therapy Designation from FDA and PRIME Status from EMA for Investigational Ebola Zaire Vaccine (V920)
Ticker: MRK
Occurred on: Jul 25, 2016
Data evaluating efficacy and safety at 48 weeks of Once-Daily Formulation of ISENTRESS (raltegravir) were presented as a late-breaking abstract at the 21st International AIDS Conference
Ticker: MRK
Occurred on: Jul 22, 2016
Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence; PDUFA date set for July 23, 2016
Ticker: MRK
Occurred on: Jul 21, 2016
Merck Animal Health Receives FDA Approval of BRAVECTO (fluralaner topical solution) for Cats and Dogs
Ticker: MRK
Occurred on: Jul 21, 2016
Incyte set to initiate Phase 3 study of epacadostat plus pembrolizumab in first-line advanced melanoma
Tickers: INCY, MRK
Occurred on: Jun 22, 2016
Merck’s KEYTRUDA (pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer
Ticker: MRK
Occurred on: Jun 16, 2016
Merck’s Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus
Ticker: MRK
Occurred on: Jun 13, 2016
Merck And Pfizer Announce Two Pivotal Phase 3 Studies For Ertugliflozin, An Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions In Patients With Type 2 Diabetes
Tickers: PFE, MRK
Occurred on: Jun 11, 2016
Merck Statement on FDA Advisory Committee Meeting for ZINPLAVA (bezlotoxumab), an Investigational Agent for Prevention of Clostridium difficile Infection Recurrence
Ticker: MRK
Occurred on: Jun 09, 2016
Merck Receives Positive CHMP Opinion for ZEPATIER (elbasvir and grazoprevir) in the European Union
Ticker: MRK
Occurred on: May 27, 2016
Merck (MRK) Expects to File NDA for DPP-4 Inhibitor Omarigliptin in Treatment of Type 2 Diabetes by End of 2016 - Cancelled
Ticker: MRK
Occurred on: Apr 08, 2016
Advaxis Combination Trial with Merck Completes First Two Dose-Escalation Cohorts
Tickers: ADXS, MRK
Occurred on: Apr 05, 2016
FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab) in Advanced Non-Small Cell Lung Cancer
Ticker: MRK
Occurred on: Mar 07, 2016
FDA’s Arthritis Advisory Committee Recommends Approval of Celltrion’s CT-P13, a Proposed Biosimilar Infliximab, for All Eligible Indications
Tickers: CELLTRION, PFE, MRK, JNJ
Occurred on: Feb 10, 2016
FDA reviewers support Celltrion's biosimilar Remicade, ahead of the Ad Comm meeting on February 9
Tickers: CELLTRION, PFE, JNJ, MRK
Occurred on: Feb 05, 2016
Merck Recieves FDA approval of ZEPATIER (elbasvirand grazoprevir) for the treatment of chronic Hepatitis C Virus genotype 1 or 4 infection in adults following priority review; the new therapy will cost $54,600 for a 12-week regimen
Tickers: MRK, GILD
Occurred on: Jan 28, 2016
Grazoprevir/Elbasvir for Treatment of Chronic Hepatitis C Genotypes 1, 4 and 6 Infection Company Granted FDA Priority Review with Target Action Date of January 28, 2016
Tickers: MRK, GILD
Occurred on: Jan 28, 2016
Merck Acquires IOmet Pharma, a privately-held UK-based drug discovery company focused on the development of innovative medicines for the treatment of cancer, with a particular emphasis on the fields of cancer immunotherapy and metabolism
Ticker: MRK
Occurred on: Jan 11, 2016
FDA Approves Expanded Indication for Merck’s KEYTRUDA (pembrolizumab) for the Treatment of Patients with Advanced Melanoma; KEYTRUDA is Now the First and Only Anti-PD-1 Therapy to Achieve Superior Overall Survival Compared to Ipilimumab
Ticker: MRK
Occurred on: Dec 18, 2015
Merck’s BRIDION (sugammadex) Receives FDA Approval for the Reversal of Neuromuscular Blockade Induced by Rocuronium and Vecuronium in Adults Undergoing Surgery
Ticker: MRK
Occurred on: Dec 17, 2015
FDA's Advisory Committee Votes in Favor of Approval of Merck's (MRK) Muscle Relaxant Reversal Agent BRIDION
Ticker: MRK
Occurred on: Nov 06, 2015
FDA Designates Merck's (MRK) KEYTRUDA a Breakthrough Therapy for Treatment of Microsatellite Instability High Metastatic Colorectal Cancer
Ticker: MRK
Occurred on: Nov 02, 2015
MacroGenics and Merck announce a collaboration to evaluate the combination of MacroGenics' margetuximab, with Merck's pembrolizumab in a Phase 1b/2 clinical trial in patients with gastric cancer
Tickers: MGNX, MRK
Occurred on: Oct 22, 2015
Merck (MRK) Receives Inquiries Over Certain Aspects of Drug Pricing
Tickers: MRK, VRX, LLY, Turing
Occurred on: Oct 19, 2015
Lilly (LLY) Receives Inquiries Over Certain Aspects of Drug Pricing (Date is an estimate for "September")
Tickers: LLY, VRX, MRK
Occurred on: Sep 15, 2015

Strategic Initiatives (MRK)

Merk (MRK) is set to acquire ArQule (ARQL) at $20 per share in cash for an approximate total equity value of $2.7 billion
Tickers: ARQL, MRK
Announcement Date: Dec 09, 2019
Merck Discontinues MK-3682B and MK-3682C Development Programs
Tickers: MRK, GILD
Announcement Date: Sep 29, 2017
Atara Bio (ATRA) Announces Clinical Trial Collaboration with Merck (MRK) Evaluating ATA129 + Keytruda in Patients with Platinum-Resistant or Recurrent EBV-Associated Nasopharyngeal Carcinoma (NPC)
Tickers: ATRA, MRK
Announcement Date: Apr 21, 2017
Lilly (LLY) and Merck (MRK) Expand Existing Oncology Collaboration, Agree to Evaluating Lartruvo + Keytruda in Advanced/Metastatic Soft Tissue Sarcoma
Tickers: LLY, MRK
Announcement Date: Jan 11, 2017
Vertex (VRTX) and Merck KgaA (MKGAY) Announce Collaboration and License Agreement Covering Four Oncology R&D Programs
Tickers: MRK, VRTX, MKGAY
Announcement Date: Jan 11, 2017
Incyte (INCY) and Merck (MRK) Expand Collaboration Agreement Investigating Epacadostat + Keytruda in Solid Tumors and Blood Cancers
Tickers: MRK, INCY
Announcement Date: Jan 09, 2017
HTG Molecular (HTGM) Agrees to Develop Companion Diagnostic Tests for Merck KGaA's (MKGAY) Cancer Candidates
Tickers: HTGM, MRK, MKGAY
Announcement Date: Oct 11, 2016
Agenus Announces Lead Product Candidate Selection in its Collaboration with Merck
Tickers: AGEN, MRK
Announcement Date: Jun 09, 2016
Merck and Sanofi Pasteur end joint vaccine operations in Europe
Tickers: SNY, MRK
Announcement Date: Mar 08, 2016
Merck KGaA, Darmstadt, Germany, Pfizer and Verastem Announce Combination Trial of Avelumab and VS-6063 in Ovarian Cancer
Tickers: MRK, PFE, VSTM
Announcement Date: Mar 03, 2016
ImmunoGen (IMGN) and Merck (MRK) Announce Research Collaboration to Evaluate IMGN's Mirvetuximab Soravtansine with Keytruda in Folate Receptor Alpha-Positive Ovarian Cancer
Tickers: MRK, IMGN
Announcement Date: Feb 04, 2016